{"name":"Duk-Woo Park, MD","slug":"duk-woo-park-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Conventional antithrombotic strategy","genericName":"Conventional antithrombotic strategy","slug":"conventional-antithrombotic-strategy","indication":"Acute coronary syndrome","status":"marketed"},{"name":"Tailored antithrombotic strategy","genericName":"Tailored antithrombotic strategy","slug":"tailored-antithrombotic-strategy","indication":"Thrombotic disease prevention and treatment (various indications including atrial fibrillation, venous thromboembolism, acute coronary syndrome)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"P-CAB 50","genericName":"P-CAB 50","slug":"p-cab-50","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"P-CAB 50","genericName":"P-CAB 50","slug":"p-cab-50","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Conventional antithrombotic strategy","genericName":"Conventional antithrombotic strategy","slug":"conventional-antithrombotic-strategy","phase":"marketed","mechanism":"Conventional antithrombotic strategy prevents blood clot formation through antiplatelet and/or anticoagulant agents to reduce thrombotic events.","indications":["Acute coronary syndrome","Atrial fibrillation for stroke prevention","Venous thromboembolism prophylaxis and treatment","Peripheral arterial disease"],"catalyst":""},{"name":"Tailored antithrombotic strategy","genericName":"Tailored antithrombotic strategy","slug":"tailored-antithrombotic-strategy","phase":"marketed","mechanism":"A personalized anticoagulation approach that tailors antithrombotic therapy selection and dosing based on individual patient characteristics, biomarkers, and clinical risk factors.","indications":["Thrombotic disease prevention and treatment (various indications including atrial fibrillation, venous thromboembolism, acute coronary syndrome)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9sRW5CTG5WN01aS2xiZFphVkZKbU5HSHpyb2plaE5jMnhXbHZnVGhpNktxMzZRYkNHU2p3U1lNUXZJNno3a0x5LTFxc3VWLVhjSHRFbXVsZWFST09GcVFNZQ?oc=5","date":"2026-03-04","type":"trial","source":"JACC Journals","summary":"Anticoagulation Alone or With Antiaggregation in Patients With Coronary Artery Disease: Meta-Analysis of Randomized Trials - JACC Journals","headline":"Anticoagulation Alone or With Antiaggregation in Patients With Coronary Artery Disease: Meta-Analysis of Randomized Tria","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNU2EwZGVjaUQ1Y0VndlRMeTl6QlExTU9JWXNwYmZXa3FsVVJfM1BCNVFNMHZMamVXRTZ2Y2tBNXZrVnQ1RlloM2F1VFV0aVhIVlB0MjBTYng3SHBuNjZSaG5fMzJHQXk5dU40OXcxUW4tazVLWlBxSlVHVnMtejk4T1M1M2Z4cVlic1RmX2xmdE82RnZjVkxN?oc=5","date":"2024-09-01","type":"pipeline","source":"TCTMD.com","summary":"Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD - TCTMD.com","headline":"Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPeXRwQkJWT1FBZzZwMU9acVhDSTl3cVVpaDQtX3FLcU5NUlpiQnBLSlFfa2k1YndTck1ZSENiTVFVN2kzS1VWU2czS2VDdFZXWmdhbjd1MG9QRUdwOVlvZm0yd1JJOUV3SVVMeDVCMmFWeXhXX2pNSllvT0lVSGpDNzdtaFBmX3VUeV9nUWNnNEU4OEJtcThDWmFlSQ?oc=5","date":"2024-03-01","type":"pipeline","source":"TCTMD.com","summary":"Even After Multivessel or LM PCI, Routine Stress Testing Adds Nothing - TCTMD.com","headline":"Even After Multivessel or LM PCI, Routine Stress Testing Adds Nothing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNZ3FRekxYYmlFUUVhRjVTREIzeE1UZkY4cmI4bW5EWEE1RnphSzFlTDBZa0JKVDQ1YWk2TzlaYS13TU5PdUFZQ1lDQWFxZW9rNkdzNUw1dGo2aXhsU29EZlQ2bFRjS09DYXRWQm8tQ3AzWnhndUZhdktsQUY4X084S2I3VURNRS1kRzBKTFd6dl84WTQ?oc=5","date":"2024-01-09","type":"pipeline","source":"TCTMD.com","summary":"TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable - TCTMD.com","headline":"TLR Rates Rise Steadily After Left Main PCI, but Deaths Stay Stable","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxORWJqRW10VXN0MWVydnA3VXlSRUliZ3N0NHFQQWlRdEhJNmNtVHdkY1lzZE43TUljLVppdW0welFlSVZlczV2WjJ6UWNLMlFJZGVMZlNXdHlDTTJ0dGF6cFVfOEIwY0tTdVQ3OWdXaURyV2VVakFyR3FINTlQSTNJcWczV0xMb0FlakNIeXVvb0xCSjQ?oc=5","date":"2022-09-06","type":"pipeline","source":"TCTMD.com","summary":"Routine Functional Testing Unnecessary After Stenting: POST-PCI - TCTMD.com","headline":"Routine Functional Testing Unnecessary After Stenting: POST-PCI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE0zSUVYd1ZOZWFaVkRKdnpGVUpwOWFGOEY1dVI2NHNXX3lUV0ItZnpwT2VKSWtFblNEMkxKa0stNnhqZlowY1Itb0Z3bnl2dENIcXpBbjJ6YWJZUHIwRHFPLQ?oc=5","date":"2022-08-28","type":"pipeline","source":"NEJM","summary":"Routine Functional Testing or Standard Care in High-Risk Patients after PCI - NEJM","headline":"Routine Functional Testing or Standard Care in High-Risk Patients after PCI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1qYXUteGpQWEI3TDZfNExKQVkxLWJ5ZFk0LU9PYTNxMDRWdVpVNlVnWmJxdVJPZXk1U2hxRTgtZlktUjQ4aV9UanZNMDN2aTZyMXBqMnpyWTZMMW1EYm9HdjFuLWU4SEF2a0FnaHc1UDFQLWlfeFJlSHlweVU?oc=5","date":"2022-04-05","type":"pipeline","source":"TCTMD.com","summary":"ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI - TCTMD.com","headline":"ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPZDVWeWIxdzNodlhLZGtzdHY1aTJUalF2alRJYVZpMU5fci1tV1gyZUxiNXMwMWk2Znh0RzYxQ3R0ZkhMSzdDOXZRc29YaUo1U3hJaDhCN3p0ak5TTmpSbm5zUkVtUDYzVGRmNVBYX0ZhR2hRajdTcDI1ellXNUlXOGZsYVhvdGVIZW5MMVBNMXNtdVZpZ2NqU1ZxSndJQQ?oc=5","date":"2019-10-03","type":"pipeline","source":"TCTMD.com","summary":"TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients - TCTMD.com","headline":"TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNd3Q0UUZUVTNmc0pXd0lsMDBjUUtQVkNQcnQxdzJYcXh2SHE3NGVVampFWUVKN3VpMGRIUUJiMTF1b0g5M3JpUkhhVW5DX0Rsc3FZZy1USmQ2cWRYbTVWSlctX0pyYXdfMl90cVBOaDR6djFrUWpKTU1iVXp6QmdNZjBVRXlCa1M2T1MxRklwaXhQUi1ESHBuWk1NVkNUSzhxTmJ0cGpB?oc=5","date":"2019-09-25","type":"pipeline","source":"ahajournals.org","summary":"Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: - ahajournals.org","headline":"Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Inte","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE15T09VcDdKdTI1eEdyMG5Rai13aHhZWXZ6bmxyakNVUzZ4OWwxYjhGX0hHTXJOWnpQZzhUdXVRSVhPanlsZlZuT21JWl9VWUdTWG5HSXk3eWRLV3dZdHV4WA?oc=5","date":"2018-04-02","type":"pipeline","source":"JACC Journals","summary":"Effect of Low-Dose Versus Standard-Dose Ticagrelor and Clopidogrel on Platelet Inhibition in Acute Coronary Syndromes - JACC Journals","headline":"Effect of Low-Dose Versus Standard-Dose Ticagrelor and Clopidogrel on Platelet Inhibition in Acute Coronary Syndromes","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}